Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827732 | 0.88 | CTBP2 (0.51) | CTBP2FFAR1CYP1A2TAAR1SIGMAR1 | |
| SCHEMBL10196980 | 0.88 | CTBP2 (0.51) | CTBP2FFAR1CYP1A2TAAR1SIGMAR1 | |
| SCHEMBL3175855 | 0.83 | CTBP2 (0.57) | CTBP2CYP1A2TAAR1SIGMAR1POLB | |
| SCHEMBL559363 | 0.81 | CTBP2 (0.49) | CTBP2FFAR1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL559283 | 0.81 | HTT (0.54) | CTBP2POLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL559379 | 0.80 | DRD2 (0.39) | CTBP2FFAR1CYP1A2 | |
| SCHEMBL31618812 | 0.79 | CTBP2 (0.60) | CTBP2CYP1A2TAAR1POLBMTNR1A | |
| SCHEMBL5322203 | 0.79 | CTBP2 (0.60) | CTBP2CYP1A2TAAR1POLBMTNR1A | |
| SCHEMBL934793 | 0.79 | TSHR (0.50) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4071390 | 0.79 | CTBP2 (0.64) | CTBP2CYP1A2TAAR1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | CTBP2 1615/4885FFAR1 2502/4885CYP1A2 149/4885 |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | CTBP2 1615/4885FFAR1 2502/4885CYP1A2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.